Analysts Set Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Target Price at $8.63

Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) have earned a consensus recommendation of "Hold" from the nine ratings firms that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation and two have given a buy recommendation to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $8.63.

Separately, HC Wainwright reiterated a "neutral" rating and issued a $4.00 price target on shares of Fulcrum Therapeutics in a report on Wednesday, February 26th.

Institutional Trading of Fulcrum Therapeutics

Hedge funds have recently modified their holdings of the business. Bank of New York Mellon Corp lifted its holdings in shares of Fulcrum Therapeutics by 2.3% during the fourth quarter. Bank of New York Mellon Corp now owns 141,873 shares of the company's stock valued at $667,000 after purchasing an additional 3,126 shares during the last quarter. American Century Companies Inc. raised its stake in Fulcrum Therapeutics by 5.9% during the fourth quarter. American Century Companies Inc. now owns 120,611 shares of the company's stock valued at $567,000 after buying an additional 6,770 shares during the last quarter. BNP Paribas Financial Markets purchased a new position in Fulcrum Therapeutics during the fourth quarter valued at $38,000. Wells Fargo & Company MN boosted its holdings in Fulcrum Therapeutics by 34.4% in the fourth quarter. Wells Fargo & Company MN now owns 34,264 shares of the company's stock worth $161,000 after acquiring an additional 8,761 shares in the last quarter. Finally, Shay Capital LLC grew its stake in shares of Fulcrum Therapeutics by 4.2% in the fourth quarter. Shay Capital LLC now owns 301,464 shares of the company's stock worth $1,417,000 after acquiring an additional 12,227 shares during the last quarter. Institutional investors own 89.83% of the company's stock.

Fulcrum Therapeutics Stock Performance

FULC stock traded down $0.05 during trading on Friday, hitting $3.60. 625,131 shares of the company traded hands, compared to its average volume of 940,005. The company has a 50-day moving average of $3.15 and a 200-day moving average of $3.61. Fulcrum Therapeutics has a 1 year low of $2.32 and a 1 year high of $10.13. The firm has a market capitalization of $194.16 million, a PE ratio of -11.59 and a beta of 2.13.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last announced its quarterly earnings results on Tuesday, February 25th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.03). Sell-side analysts expect that Fulcrum Therapeutics will post -0.16 EPS for the current year.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.